BlackThorn Therapeutics

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company established in 2015, specializing in precision medicine for central nervous system (CNS) disorders. The company's unique approach involves leveraging advanced computational and clinical neuroscience insights to target dysfunctional brain circuits. This allows them to address traditional challenges in drug discovery and development. Through its proprietary computational platform, BlackThorn aims to identify novel targets, small molecule drug candidates, and biologically-based patient subgroups most likely to respond to treatment.

The company's slogan "Pioneering precision medicine for CNS disorders through advanced computational and clinical neuroscience" aligns with its vision and objectives. The recent Series B investment of $76.00M on 13 June 2019, led by prominent investors including Arch Venture Partners, GV, Biomatics Capital Partners, Premier Partners, Alexandria Venture Investments, Vertex Ventures HC, Johnson & Johnson Innovation – JJDC, The Scripps Research Institute, Altitude Life Science Ventures, and Mercury underscores the confidence the investment community has in BlackThorn Therapeutics' innovative approach and potential for impact in the field of CNS disorders.

BlackThorn Therapeutics' focus on merging AI, biotechnology, and healthcare to drive advancements in the treatment of CNS disorders positions the company at the forefront of pioneering medical breakthroughs. This, coupled with their strong investor support and strategic partnerships, sets the stage for considerable growth and future success within the healthcare and biotechnology industries.